Insight

Mohan Uttarwar: 19 of our abstracts have been accepted at ASCO 2025 Annual Meeting

Mohan Uttarwar/LinkedIn

May 17, 2025, 10:11

Mohan Uttarwar: 19 of our abstracts have been accepted at ASCO 2025 Annual Meeting

Mohan Uttarwar, Cofounder and CEO of OneCell Diagnostics India Pvt Ltd shared a post on LinkedIn:

“This year, 19 of our abstracts have been accepted at ASCO 2025.

And I’ll be honest, I’m still letting that sink in.

It is more than just a number for us.

Why? Because ASCO is the global stage for oncology research. Abstracts here don’t just get submitted. They get scrutinized. Reviewed by world-class experts. Rated on novelty, clinical impact, and translational potential. The bar is high.

To our incredible team— Jayant Khandare, Aravindan Vasudevan, Atul Bharde, Hrishita Kothavade, Aarthi Ramesh, Dr. Gowhar S. and so many others—this achievement is a testament to your hard work, brilliance, and unwavering commitment. Thank you for making the seemingly impossible, possible.

I am also deeply thankful to the American Society of Clinical Oncology (ASCO) reviewers for their thoughtful evaluations, our research collaborators for their trust and partnership, and most importantly, the patients whose strength and stories inspire and guide every step of our journey.

We have built 1Cell.Ai Inc. to bring more clarity to something that often feels uncertain. Our platform doesn’t just detect cancer—it decodes it. From a simple blood draw, we isolate even the rarest tumor cells and use AI to help make sense of what they’re telling us, empowering doctors to make faster and smarter decisions.

If you’re attending ASCO 2025, I’d love to connect and discuss how we can make an even greater impact together.”

ASCO ASCO Mohan Uttarwar: 19 of our abstracts have been accepted at ASCO 2025 Annual Meeting